MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
0.7204
-0.0135 (-1.84%)
At close: Feb 13, 2026, 4:00 PM EST
0.7196
-0.0008 (-0.11%)
After-hours: Feb 13, 2026, 5:56 PM EST
MaxCyte Employees
MaxCyte had 114 employees as of December 31, 2024. The number of employees decreased by 29 or -20.28% compared to the previous year.
Employees
114
Change (1Y)
-29
Growth (1Y)
-20.28%
Revenue / Employee
$301,921
Profits / Employee
-$400,272
Market Cap
76.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 114 | -29 | -20.28% |
| Dec 31, 2023 | 143 | 18 | 14.40% |
| Dec 31, 2022 | 125 | 41 | 48.81% |
| Dec 31, 2021 | 84 | 19 | 29.23% |
| Mar 31, 2021 | 65 | 0 | - |
| Dec 31, 2019 | 65 | - | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Accuray | 990 |
| Neuronetics | 716 |
| Outset Medical | 354 |
| Pulmonx | 291 |
| Xtant Medical Holdings | 232 |
| Hyperfine | 111 |
| Picard Medical | 75 |
| InspireMD | 66 |
MXCT News
- 4 weeks ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Business Wire
- 3 months ago - MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - MaxCyte Announces Planned CFO Transition in 2026 - GlobeNewsWire
- 3 months ago - MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - GlobeNewsWire
- 3 months ago - MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - GlobeNewsWire
- 4 months ago - MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 4 months ago - MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - GlobeNewsWire